Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.607 / 17.026
#124849

Re: Farmas USA

ARQT 
Offering a 25$, orbimed compra 500.000 acciones, que añade a su posición de 560.000 acciones que tenia a 17$ de la IPO

Hacen una crema para psoriasis, en fase 3, dicen que es un 25-300x veces más efectiva que los tratamientos que hay, y que a diferencia de ellos que son esteroides, el suyo no tiene esteroides con la ventaja que eso conlleva para una enfermedad crónica ( no usar esteroides) y más segura y tolerable. 


Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical or systemic treatment of plaque psoriasis and atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis. Roflumilast is 25–300X more potent than the two other FDA-approved PDE4 inhibitors used in dermatology and has a well-established safety profile with more than 1 million patient years of exposure in clinical use.

In our plaque psoriasis development program, we have completed a 332-patient Phase 2b study and an 89-patient Phase 2a study of topical roflumilast cream. In the recent Phase 2b study, topical roflumilast cream produced statistically significant reductions compared to vehicle in the signs of plaque psoriasis, and also demonstrated excellent safety and tolerability in this population. We also recently completed two pivotal Phase 3 studies of topical roflumilast cream in plaque psoriasis, and expect to release data from those trials in Q1 2021. 

#124851

Re: Farmas USA

In 12,75
ALT
#124852

Re: Farmas USA

otra que no me deja comprar ING
 ARQT
#124854

Re: Farmas USA

Enhorabuena por esos cortos.

Mi garantía en IG con CFD de Nvax es del 25% , con independencia de si son largos o cortos.

Con Amrn igual.


#124856

Re: Farmas USA

Las garantías van en relación al nominal de la acción.
Si te pones corto en AMZN ni te digo,,,
Al fin y al cabo tienen que considerar cobertura de una gran posible caída y más con estas bichas tan volátiles, eso contará en el cálculo.
AMRN poca cosa a 5 dólares te habrán pedido, comparativamente.

Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.